Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
H5N1 VLP Vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Low dose H5N1 VLP Vaccine | EXPERIMENTAL | - |
| Mid dose H5N1 VLP Vaccine | EXPERIMENTAL | - |
| High dose H5N1 VLP Vaccine | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| H5N1 VLP Vaccine | BIOLOGICAL | Two doses - Day 0 \& Day 28 |
| Placebo | BIOLOGICAL | Two doses - Day 0 \& Day 28 |
Inclusion Criteria: 1. Male or female 18 to 40 years of age at the time of the vaccination. 2. Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., return for follow-up visits and completion of the data collection tool). 3. Available by telephone. ...
The H5N1 VLP Vaccine is an investigational vaccine developed by Novavax, Inc. for pandemic influenza. It is a virus-like particle (VLP) vaccine designed to protect against H5N1 influenza, a strain with pandemic potential. It has been studied in a Phase 1 clinical trial.
The H5N1 VLP Vaccine is being developed for the prevention of pandemic influenza caused by the H5N1 virus. It is intended to stimulate an immune response against H5N1 influenza. The vaccine is investigational and has been evaluated in a Phase 1 trial.
The H5N1 VLP Vaccine is developed by Novavax, Inc., a biotechnology company traded on the Nasdaq under the ticker symbol NVAX. Novavax specializes in vaccine development, including virus-like particle (VLP) and recombinant protein technologies.
The H5N1 VLP Vaccine is in Phase 1 clinical development. It has completed one Phase 1 trial (NCT00519389) evaluating its safety, reactogenicity, and immunogenicity. It is not approved by the FDA and remains investigational.
The H5N1 VLP Vaccine has been studied in one completed Phase 1 clinical trial, NCT00519389, titled "Safety, Reactogenicity and Immunogenicity of an H5N1 VLP." The trial enrolled 230 healthy adult volunteers in the United States and was randomized, double-blind, and placebo-controlled.